Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Tan J.K.; Awuah W.A.; Roy S.; Ferreira T.; Ahluwalia A.; Guggilapu S.; Javed M.; Asyura M.M.A.Z.; Adebusoye F.T.; Ramamoorthy K.; Paoletti E.; Abdul-Rahman T.; Prykhodko O.; Ovechkin D.
Tan, Joecelyn Kirani (58523295900); Awuah, Wireko Andrew (57444461300); Roy, Sakshi (58146940700); Ferreira, Tomas (58098728500); Ahluwalia, Arjun (58189612300); Guggilapu, Saibaba (58712741000); Javed, Mahnoor (57225344627); Asyura, Muhammad Mikail Athif Zhafir (57256325200); Adebusoye, Favour Tope (58153722300); Ramamoorthy, Krishna (58776921600); Paoletti, Emma (58533912600); Abdul-Rahman, Toufik (57576497300); Prykhodko, Olga (57195981037); Ovechkin, Denys (57201667375)
58523295900; 57444461300; 58146940700; 58098728500; 58189612300; 58712741000; 57225344627; 57256325200; 58153722300; 58776921600; 58533912600; 57576497300; 57195981037; 57201667375
Exploring the advances of single-cell RNA sequencing in thyroid cancer: a narrative review
2024
Medical Oncology
41
1
27
1
Faculty of Medicine, University of St Andrews, St Andrews, Scotland, United Kingdom; Faculty of Medicine, Sumy State University, Sumy, Ukraine; School of Medicine, Queen’s University Belfast, Belfast, United Kingdom; School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; Faculty of Medicine, Bangalore Medical College and Research Institute, Bengaluru, India; School of Medicine, The University of Nottingham, Nottingham, NG7 2UH, United Kingdom; Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Rutgers University-New Brunswick, New Brunswick, 08854, NJ, United States; Faculty of Medicine, University of Manchester, Manchester, M13 9WJ, United Kingdom
Tan J.K., Faculty of Medicine, University of St Andrews, St Andrews, Scotland, United Kingdom; Awuah W.A., Faculty of Medicine, Sumy State University, Sumy, Ukraine; Roy S., School of Medicine, Queen’s University Belfast, Belfast, United Kingdom; Ferreira T., School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; Ahluwalia A., School of Medicine, Queen’s University Belfast, Belfast, United Kingdom; Guggilapu S., Faculty of Medicine, Bangalore Medical College and Research Institute, Bengaluru, India; Javed M., School of Medicine, The University of Nottingham, Nottingham, NG7 2UH, United Kingdom; Asyura M.M.A.Z., Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Adebusoye F.T., Faculty of Medicine, Sumy State University, Sumy, Ukraine; Ramamoorthy K., Rutgers University-New Brunswick, New Brunswick, 08854, NJ, United States; Paoletti E., Faculty of Medicine, University of Manchester, Manchester, M13 9WJ, United Kingdom; Abdul-Rahman T., Faculty of Medicine, Sumy State University, Sumy, Ukraine; Prykhodko O., Faculty of Medicine, Sumy State University, Sumy, Ukraine; Ovechkin D., Faculty of Medicine, Sumy State University, Sumy, Ukraine
Thyroid cancer, a prevalent form of endocrine malignancy, has witnessed a substantial increase in occurrence in recent decades. To gain a comprehensive understanding of thyroid cancer at the single-cell level, this narrative review evaluates the applications of single-cell RNA sequencing (scRNA-seq) in thyroid cancer research. ScRNA-seq has revolutionised the identification and characterisation of distinct cell subpopulations, cell-to-cell communications, and receptor interactions, revealing unprecedented heterogeneity and shedding light on novel biomarkers for therapeutic discovery. These findings aid in the construction of predictive models on disease prognosis and therapeutic efficacy. Altogether, scRNA-seq has deepened our understanding of the tumour microenvironment immunologic insights, informing future studies in the development of effective personalised treatment for patients. Challenges and limitations of scRNA-seq, such as technical biases, financial barriers, and ethical concerns, are discussed. Advancements in computational methods, the advent of artificial intelligence (AI), machine learning (ML), and deep learning (DL), and the importance of single-cell data sharing and collaborative efforts are highlighted. Future directions of scRNA-seq in thyroid cancer research include investigating intra-tumoral heterogeneity, integrating with other omics technologies, exploring the non-coding RNA landscape, and studying rare subtypes. Overall, scRNA-seq has transformed thyroid cancer research and holds immense potential for advancing personalised therapies and improving patient outcomes. Efforts to make this technology more accessible and cost-effective will be crucial to ensuring its widespread utilisation in healthcare. © 2023, The Author(s).
Medical oncology; Personalised medicine; Single-cell RNA sequencing; Thyroid cancer; Tumour heterogeneity; Tumour microenvironment
Artificial Intelligence; Cell Communication; Gene Expression Profiling; Humans; Machine Learning; Sequence Analysis, RNA; Thyroid Neoplasms; Tumor Microenvironment; untranslated RNA; artificial intelligence; cancer research; cell communication; cell subpopulation; deep learning; human; machine learning; predictive model; Review; single cell RNA seq; thyroid cancer; treatment outcome; tumor microenvironment; artificial intelligence; gene expression profiling; genetics; RNA sequencing; thyroid tumor
Springer
13570560
38129369
Review
Q2
777
6221